A. Anagnostopoulos

U. Popat, M. Qazilbash, D. Couriel, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell transplantation (SCT) for Waldenstrom's macroglobulinemia (WM)

A. Anagnostopoulos, S. Giralt, 2002, Bone Marrow Transplantation.

Successful non‐myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome

M. Andreeff, N. Ueno, S. O'brien, 2002, British journal of haematology.

Renal Failure in Multiple Myeloma: Incidence, Correlations and Prognostic Significance.

M. Dimopoulos, E. Kastritis, A. Symeonidis, 2006 .

Comparison of high‐dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

G. Ayers, R. Champlin, A. Anagnostopoulos, 2004, Cancer.

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

N. Ueno, A. Anagnostopoulos, D. Weber, 2002, Bone Marrow Transplantation.

Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.

E. Kimby, M. Dimopoulos, D. Maloney, 2006, Blood.

Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin‐1 to angiopoietin‐2 and angiogenin correlate with disease severity

M. Dimopoulos, E. Kastritis, E. Terpos, 2007, British journal of haematology.

Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece

M. Dimopoulos, D. Gika, A. Anagnostopoulos, 2002, Annals of Hematology.

Critical review on non-myeloablative stem cell transplantation (NST).

A. Anagnostopoulos, S. Giralt, S. Giralt, 2002, Critical reviews in oncology/hematology.

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

A. Pestronk, N. Munshi, S. Treon, 2003, Seminars in oncology.

Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support.

M. Dimopoulos, E. Kastritis, E. Terpos, 2006, Clinical lymphoma & myeloma.

Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

Michael L. Wang, A. Anagnostopoulos, D. Weber, 2003, Seminars in hematology.

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.

K. Zervas, A. Anagnostopoulos, M. Papaioannou, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Thalidomide and dexamethasone for resistant multiple myeloma

A. Anagnostopoulos, D. Weber, R. Alexanian, 2003, British journal of haematology.

Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.

M. Dimopoulos, N. Pavlidis, C. Papadimitriou, 1998, Gynecologic oncology.

Chronic graft-versus-host disease manifesting as polymyositis: an uncommon presentation

D. Couriel, R. Champlin, A. Anagnostopoulos, 2002, Bone Marrow Transplantation.

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.

E. Estey, B. Andersson, P. Cano, 2003, Blood.

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.

M. Munsell, J. Cortes, N. Ueno, 2004, Blood.

Recurrent mutations refine prognosis in chronic lymphocytic leukemia

E. Campo, N. Villamor, J. Delgado, 2014, Leukemia.

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma.

M. Dimopoulos, E. Efstathiou, D. Gika, 2004, The hematology journal : the official journal of the European Haematology Association.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

A. Alousi, R. Champlin, M. de Lima, 2007, Blood.

Postoperative Treatment With Docetaxel, Cisplatin, and Capecitabine (DCX) and Chemoradiotherapy (CRT) With Capecitabine for Resected Gastric Adenocarcinoma

V. Georgoulias, I. Boukovinas, J. Souglakos, 2015, American journal of clinical oncology.

Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements

K. Stamatopoulos, I. Chouvarda, Š. Pospíšilová, 2017, Leukemia.

Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.

H. Gogas, C. Markopoulos, T. Economopoulos, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer

M. Dimopoulos, P. Athanassiades, A. Keramopoulos, 1998, Oncology.

Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens

D. Anagnostou, A. Anagnostopoulos, G. Hamilos, 2004, Leukemia & lymphoma.

Diagnosis and management of Waldenstrom's macroglobulinemia.

Robert A Kyle, M. Dimopoulos, R. Kyle, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of receptor activator of nuclear factor‐kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1‐alpha (MIP‐1a) in monoclonal gammopathy of undetermined significance (MGUS)

M. Dimopoulos, E. Terpos, M. Laffan, 2004, British journal of haematology.

VAD-doxil vs.VAD-doxil Plus Thalidomide as Initial Treatment in Patients with Multiple Myeloma: A Multicenter Randomized Trial of the Greek Myeloma Study Group.

M. Dimopoulos, M. Kyrtsonis, E. Terpos, 2006 .

Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma

M. Dimopoulos, P. Sfikakis, E. Terpos, 2006, Haematologica.

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.

M. Dimopoulos, M. Kyrtsonis, E. Katodritou, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.

M. Dimopoulos, G. Fountzilas, A. Bamias, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel.

M. Dimopoulos, C. Papadimitriou, D. Mitropoulos, 1998, Urology.

Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.

M. Dimopoulos, E. Kastritis, E. Terpos, 2007 .

Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

M. Dimopoulos, M. Kyrtsonis, A. Vassou, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia

R. Champlin, A. Anagnostopoulos, D. Weber, 2001, Bone Marrow Transplantation.

Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.

H. Goldschmidt, P. Hari, D. Reece, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of Waldenstrom’s Macroglobulinemia

M. Dimopoulos, A. Anagnostopoulos, 2007, Current treatment options in oncology.

Plasma Cell Dyscrasias Treatment of Waldenstrom ’ s Macroglobulinemia

M. Dimopoulos, A. Anagnostopoulos, 2007 .

Autologous and allogeneic stem cell transplantation in Waldenstrom's macroglobulinemia: review of the literature and future directions.

A. Anagnostopoulos, S. Giralt, A. Alemán, 2003, Seminars in oncology.

Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment.

M. Dimopoulos, M. Kyrtsonis, K. Zervas, 2006, Clinical Lymphoma & Myeloma.

Workshop on Waldenström's Macroglobulinemia Update on treatment recommendations from the Third International

E. Kimby, M. Dimopoulos, D. Maloney, 2008 .

Primary Treatment of Waldenstrom’s Macroglobulinemia (WM) with Dexamethasone, Rituximab and Cyclophosphamide.

M. Dimopoulos, T. Economopoulos, M. Kyrtsonis, 2004 .

Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.

M. Dimopoulos, A. Anagnostopoulos, C. Zervas, 2005, Clinical lymphoma.

The International Staging System for Multiple Myeloma is Applicable in Symptomatic Waldenstrom's Macroglobulinemia

M. Dimopoulos, M. Kyrtsonis, K. Zervas, 2004, Leukemia & lymphoma.

Rituximab therapy in monoclonal IgM-related neuropathies

M. Dimopoulos, N. Karandreas, A. Anagnostopoulos, 2006, Leukemia & lymphoma.

Treatment of plasma cell dyscrasias with thalidomide and its derivatives.

M. Dimopoulos, A. Anagnostopoulos, D. Weber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Stem Cell Support: a New Regimen for the Treatment of Multiple Myeloma

R. Champlin, M. de Lima, A. Anagnostopoulos, 2004, Leukemia & lymphoma.

Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.

M. Dimopoulos, G. Fountzilas, C. Papadimitriou, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

M. Dimopoulos, D. Heath, P. Croucher, 2006, International journal of cancer.

Hematological malignancies: myeloma.

A. Anagnostopoulos, M. Dimopoulos, E. Kastritis, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

educational session Hematological malignancies

A. Anagnostopoulos, M. Dimopoulos, E. Kastritis, 2006 .

Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy

A. Anagnostopoulos, D. Weber, S. Giralt, 2004, Bone Marrow Transplantation.

allogeneic hematopoietic stem cell transplantation syndrome: dose is relevant for long-term disease control after treatment of acute myeloid leukemia and high-risk myelodysplastic Nonablative versus reduced-intensity conditioning regimens in the

M. Munsell, J. Cortes, N. Ueno, 2013 .

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

M. Dimopoulos, D. Heath, P. Croucher, 2006, British journal of haematology.

Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.

L. Moulopoulos, D. Gika, A. Anagnostopoulos, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.

I. Papassotiriou, A. Margeli, E. Terpos, 2006, Kidney international.

Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.

M. Dimopoulos, M. Kyrtsonis, A. Vassou, 2006, Haematologica.

Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.

A. Bamias, C. Deliveliotis, E. Efstathiou, 2004, Urology.

Abnormal bone remodelling and increased levels of macrophage inflammatory protein‐1 alpha (MIP‐1α) in Waldenström macroglobulinaemia

M. Dimopoulos, E. Kastritis, E. Terpos, 2006, British journal of haematology.

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

M. Dimopoulos, D. Heath, P. Croucher, 2006 .

Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors

M. Dimopoulos, E. Kastritis, K. Zervas, 2004, Leukemia & lymphoma.

Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.

M. Dimopoulos, A. Anagnostopoulos, 2003, Seminars in hematology.

Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis

M. Dimopoulos, E. Terpos, A. Anagnostopoulos, 2005, Leukemia & lymphoma.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

M. Dimopoulos, E. Kastritis, E. Terpos, 2005 .

CLL: Different ages, dfferent antigen receptor profiles

K. Stamatopoulos, N. Darzentas, N. Chiorazzi, 2013 .

Implications of prominent cytologic dysplasia persisting in the marrow of a patient with CML even after the spontaneous disappearance of the Philadelphia chromosome

A. Anagnostopoulos, A. Bogdanović, M. Andolina, 1996, American journal of hematology.

Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study.

D. Trafalis, A. Anagnostopoulos, A. Anagnostopoulos, 2010, Oncology letters.

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

M. Dimopoulos, D. Skarlos, A. Anagnostopoulos, 2003, Urology.

Diagnosis and management of Waldenstrom's macroglobulinemia.

M. Dimopoulos, R. Kyle, S. Treon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Waldenström's macroglobulinemia.

M. Dimopoulos, A. Anagnostopoulos, 2005, Best practice & research. Clinical haematology.

Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma ≥ 75 Years of Age.

M. Dimopoulos, A. Vassou, E. Katodritou, 2004 .